Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data

Authors: O’Brien Z, Fallah Moghaddam M
Publication: Expert Opin Drug Metab Toxicol
Keywords: biological availability, Caco-2 cells, chemical phenomena, cytochrome P-450 CYP3A, drug evaluation, drug interactions, humans, permeability, pharmacokinetics, preclinical, protein kinase inhibitors, solubility, United States Food and Drug Administration
Software: ADMET Predictor®

Introduction

Fourteen drugs targeting protein kinases have been approved by the United States Food and Drug Administration (FDA) between the years 2000 and 2011. While the mechanisms of action and clinical data have been reported, the preclinical absorption, distribution, metabolism and elimination (ADME) data on these compounds are not readily available.